Biotech Growth Trust Plc – Annual Report Snapshot 2026

Biotech Growth Trust Plc

Biotech Growth Trust Plc (LON:BIOG) has published its Annual Report for 2026, giving shareholders and prospective investors a clear overview of the Trust’s performance, strategy and portfolio positioning.

The dedicated Annual Report section on the company’s website provides quick and easy access to key parts of the report, allowing readers to navigate directly to the areas most relevant to them.

Visitors can use the page to explore sections including Financial Highlights, the Portfolio Manager’s Review, KPIs, Historic Performance, the Chair’s Statement and Downloads.

The Portfolio Manager’s Review highlights the continued opportunity across the biotechnology sector.

“Despite the strong performance of the Company during the year, we believe we are still in the early stages of a sustained recovery. Many of the macroeconomic and political overhangs that weighed on the sector in the early part of the year have been resolved. Scientific innovation fuelling medical advancements remains robust. Biotechnology companies continue to develop first-in-class drugs addressing unmet medical needs.”

Geoff Hsu & Josh Golomb,
OrbiMed Capital LLC, Portfolio Manager

The Chair’s Statement also points to the strength of the Trust’s performance drivers during the year.

“The Board is encouraged by the breadth and quality of the drivers underpinning the Company’s performance during the year, with returns led in particular by strong contributions from small and mid-capitalisation biotechnology companies. While we remain mindful of the inherent volatility of both the sector and the Company’s active approach, it is reassuring to see the portfolio respond strongly as conditions improved and investment theses were realised.”

Roger Yates,
Chair

For quick access to the different sections of the 2026 Annual Report, visit the Biotech Growth Trust Annual Report page here:

www.biotechgt.com/corporate-information/annual-report-2026

Biotech Growth Trust Plc is an investment trust focused on biotechnology companies, aiming to deliver long-term capital growth by investing in businesses developing medical treatments and healthcare innovations.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Biotech Growth Trust shares rise 22.9% as five portfolio companies agree takeovers

Biotech Growth Trust recorded a 22.9% total return on its share price in the six months to September 2026,...

Biotech Growth Trust reports 16.5% annual share price return as NAV rises 16%

Biotech Growth Trust reported a 16.5% one-year total return on its share price and a 16.0% increase in NAV...

Cancer research advances bring new treatment options and improve patient outcomes

Advances in cancer research are expanding treatment options, improving early detection and developing more personalised approaches....

Drug development continues to create opportunities for medical innovation

The development of new medicines combines scientific research, clinical trials and regulatory review to bring potential treatments closer to...

The Biotech Growth Trust: Recent Sector Weakness Could Present an Opportunity, Says Kepler Partners

The Biotech Growth Trust could benefit from renewed pharmaceutical acquisitions and biotechnology innovation, according to Kepler Partners research....

Biotech Growth Trust positioned to benefit from sector recovery: Kepler

Kepler research highlights the potential for Biotech Growth Trust (BIOG) to benefit from a recovery in biotech stocks, supported...

Search